October 01, 2016 12:02 PM ET

Biotechnology

Company Overview of Envisia Therapeutics Inc.

Company Overview

Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2013

Phone:

919-973-1440

Fax:

919-973-1441

Key Executives for Envisia Therapeutics Inc.

Chief Executive Officer and Director
Age: 54
Co-Founder, President and Chief Scientific Officer
Age: 50
Executive Chairman
Chief Financial Officer
Chief Medical Officer
Compensation as of Fiscal Year 2016.

Envisia Therapeutics Inc. Key Developments

Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM

Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.

Envisia Therapeutics Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-17-2016 03:40 PM

Envisia Therapeutics Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-17-2016 03:40 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.

Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma

Envisia Therapeutics reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). ENV515, the company's product candidate, is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. Previously, a 28-day evaluation of the low dosage form of ENV515 demonstrated a reduction in IOP comparable to topical timolol, while the high dosage form of ENV515 demonstrated results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution). This second cohort of the ongoing phase 2 trial was a 12-month safety and efficacy evaluation of the low dosage form of ENV515 that was designed as an open-label trial that enrolled five glaucoma patients at sites within the U.S. The low dosage form of ENV515, administered once on Day 1, achieved the interim efficacy endpoint in this 3-month analysis, time-matched 8 AM IOP over the three-month post-dose period, with -7.1 mmHg or -27% change from IOP baseline that was comparable to topical timolol 0.5% twice daily with -7.4 mmHg or -28% change from IOP baseline, administered to the non-study eye. ENV515 was well tolerated and there were no serious adverse events, no changes in corneal endothelial cell counts evaluated by an independent reading center, and no changes in corneal thickness. The most common adverse event was early-onset transient hyperemia, or eye redness, related to the dosing procedure. ENV515 is a fully biodegradable proprietary PRINT® nanoparticle formulation of a marketed prostaglandin analog that has the potential to lower IOP for more than six months from a single dose. ENV515 has the potential to address the issue of poor patient compliance that exists present with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the company's unique platform technology to develop products for other leading ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 11, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Envisia Therapeutics Inc., please visit www.envisiatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.